Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have received an average recommendation of “Buy” from the four research firms that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock […]
HBK Sorce Advisory LLC lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 49.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,147 shares of the biopharmaceutical company’s stock after selling 11,071 shares during the quarter. HBK Sorce […]
Victory Capital Management Inc. grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 293,658 shares of the biopharmaceutical company’s stock after acquiring an additional 4,709 shares during the quarter. Victory Capital Management […]
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) had its target price hoisted by Piper Sandler from $21.00 to $24.00 in a research report report published on Wednesday morning, The Fly reports. Several other brokerages also recently commented on CPRX. Cantor Fitzgerald lifted their price target on Catalyst Pharmaceuticals from $22.00 to $25.00 in a research report […]